# Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,

Source: https://onco.cc/trials/nct07271355/  
OnCo record `nct07271355` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of bevacizumab (glioblastoma use), fluorouracil (5-FU), irinotecan (and liposomal irinotecan), leucovorin (folinic acid) and other drugs in colorectal cancer, run by City of Hope Medical Center, not yet recruiting.

## Summary

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial is a phase 3, randomised interventional study registered as NCT07271355 by City of Hope Medical Center, with a registry enrolment figure of 129 participants, started 2026-10-01 and due to reach its primary completion in 2031-02-28. Interventions recorded: Bevacizumab; Biopsy Procedure; Biospecimen Collection; Computed Tomography; Fluorouracil; Irinotecan Hydrochloride; Leucovorin Calcium; Magnetic Resonance Imaging; Mitomycin; Questionnaire Administration. Conditions listed: Metastatic Appendix Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Malignant Neoplasm in the Peritoneum; Stage IV Appendix Carcinoma AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Colorectal Carcinoma. Primary outcome: Overall survival (OS). Colorectal eligibility wording from the registry: "* Histologically or cytologically confirmed appendiceal or colorectal cancer peritoneal metastases". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07271355
- Phase: 3
- Setting: Investigation of Mitomycin C PIPAC - FOLFIRI Combination for Unresectable Appendiceal or Colorectal Peritoneal Metastases Treatment (IMPACT): A Multicenter, Randomized, Open-Label, Phase 3 Trial
- Sponsor: City of Hope Medical Center
- Enrolled: 129

## Sources

- ClinicalTrials.gov NCT07271355: https://clinicaltrials.gov/study/NCT07271355

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [HIPEC / PIPAC (intraperitoneal chemotherapy)](https://onco.cc/technologies/hipec/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Mitomycin C](https://onco.cc/drugs/mitomycin/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07271355.json